{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IMGN853", "query": { "intervention": "IMGN853" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IMGN853&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T15:36:03.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04209855", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epithelial Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 453, "start_date": "2019-12-31", "completion_date": "2024-10-29", "has_results": true, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209855" }, { "nct_id": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Sofetabart Mipitecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "MIRV", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1630, "start_date": "2025-10-22", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213804" }, { "nct_id": "NCT02631876", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epithelial Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 366, "start_date": "2016-03-02", "completion_date": "2020-01", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631876" }, { "nct_id": "NCT06890338", "title": "A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "Neoadjuvant" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Mirvetuximab Soravtansine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 140, "start_date": "2025-11-21", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06890338" }, { "nct_id": "NCT07218809", "title": "AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epithelial Ovarian Cancer" ], "interventions": [ { "name": "AZD5335", "type": "DRUG" }, { "name": "Mirvetuximab Soravtansine (MIRV)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal Doxorubicin (PLD)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1100, "start_date": "2025-12-29", "completion_date": "2029-12-27", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218809" }, { "nct_id": "NCT03832361", "title": "Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "IMGN853", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alessandro Santin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 50, "start_date": "2020-07-15", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03832361" }, { "nct_id": "NCT03836157", "title": "Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Endometrial Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2019-05-31", "completion_date": "2022-05", "has_results": false, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03836157" }, { "nct_id": "NCT03552471", "title": "Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Folate Receptor Alpha Positive", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Recurrent Uterine Serous Carcinoma", "Recurrent Uterine Carcinosarcoma", "Platinum Resistant Ovarian Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mirvetuximab Soravtansine", "type": "BIOLOGICAL" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Rucaparib Camsylate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2018-07-12", "completion_date": "2022-12-19", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03552471" }, { "nct_id": "NCT03106077", "title": "Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Negative", "Folate Receptor Alpha Positive", "HER2/Neu Negative", "Progesterone Receptor Negative", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2017-06-05", "completion_date": "2019-10-01", "has_results": true, "last_update_posted_date": "2020-12-02", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03106077" }, { "nct_id": "NCT05041257", "title": "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 79, "start_date": "2021-10-19", "completion_date": "2024-12-12", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-09-07T15:36:03.197Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05041257" } ] }